In addition, a recent salvage therapy case for a patient with anaplastic thyroid cancer treated with the B-Raf inhibitor, dabrafenib, and the MEK1/2 inhibitor, trametinib, utilized rpS6 phosphorylation status as an indicator for a lack of responsiveness to this therapy, which prompted the addition of the mTOR inhibitor, everolimus, which promoted a dramatic regression in tumor volume31. This evidence concerns the gene MTOR and neoplasm.